← COLLEGIUM PHARMACEUTICAL, INC

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent ($94.2m) ($74.9m) ($39.1m) ($22.7m) $26.8m $71.5m ($25.0m) $48.2m $69.2m $62.9m
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest — — — — — — ($25.0m) $48.2m $69.2m $62.9m
Depreciation, Depletion and Amortization $655k $594k $1.1m $731k $870k $1.7m $2.7m $3.5m $3.9m $4.2m
Depreciation $258k $336k $1.1m $731k $870k $1.7m $2.7m $3.5m $3.9m $4.2m
Amortization of Debt Issuance Costs and Discounts — — — — $9.0m $3.4m $8.3m $8.6m $6.0m $5.3m
Amortization of Intangible Assets $397k — $109.8m $14.8m $60.7m $67.2m — — — $221.9m
Deferred Income Tax Expense (Benefit) — — — — — ($78.0m) ($8.4m) ($2.2m) ($26.8m) ($25.7m)
Share-based Payment Arrangement, Noncash Expense $5.8m $7.9m $13.8m $16.5m $21.9m $24.3m $22.9m $27.1m $32.4m $41.9m
Payment, Tax Withholding, Share-based Payment Arrangement — $68k $560k $822k $2.3m $4.1m $4.0m $8.4m $19.2m $12.8m
Share-based Payment Arrangement, Expense $5.8m $7.9m $13.8m $16.5m $21.9m $24.3m $22.9m $27.1m $32.4m —
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) — $1.8m — — — — — — — —
Gain (Loss) on Extinguishment of Debt — — — — — — — ($23.5m) ($11.3m) ($16.0m)
Income Tax Expense (Benefit) — — — — $830k ($74.9m) ($3.8m) $27.6m $29.4m $29.7m
Interest Expense Nonoperating — — — — — — — — $74.0m $82.3m
Other Nonoperating Income (Expense) ($94k) $582k — — — — — — — —
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Accounts Receivable ($2.1m) $7.8m $68.2m ($5.0m) $10.4m $22.5m $21.8m ($3.6m) $4.4m ($17.2m)
Increase (Decrease) in Inventories ($1.3m) $497k ($219k) $1.8m $8.3m $2.3m ($48.3m) ($14.2m) ($13.9m) $5.4m
Increase (Decrease) in Accounts Payable $5.6m ($3.4m) $6.5m ($5.9m) $3.8m ($5.8m) ($707k) $5.1m ($11.3m) $6.7m
Proceeds from Stock Options Exercised $443k $736k $4.3m $2.0m $6.6m $12.0m $11.8m $8.6m $10.2m $4.3m
Goodwill — — — — — — $133.7m $133.9m $162.3m $145.9m
Operating Expenses $95.8m — — — $123.6m $133.0m $176.2m $159.2m $207.4m $283.6m
Revenue from Contract with Customer, Including Assessed Tax — — $280.4m — — — — — — —
Net Cash Provided by (Used in) Operating Activities ($75.1m) ($67.0m) $169.4m $27.8m $93.9m $103.6m $124.2m $274.7m $205.0m $329.3m
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $477k $990k $5.5m $6.4m $5.5m $1.9m $1.6m $461k $1.7m $1.7m
Payments to Acquire Businesses, Net of Cash Acquired — — — — — — $572.1m — — $0
Net Cash Provided by (Used in) Investing Activities ($3.0m) ($990k) ($24.4m) ($6.4m) ($373.8m) ($1.9m) ($573.7m) ($70.8m) ($287.8m) ($63.5m)
Cash flows from financing activities:
Proceeds from Issuance of Long-term Debt — — $10.0m — — — — $0 $0 —
Repayments of Long-term Debt — $2.7m — — $11.5m — — — — —
Proceeds from Issuance of Common Stock $137.3m $34.3m ($30k) $817k $758k $755k $337k $460k $827k $1.4m
Payments for Repurchase of Common Stock — — — — — $47.9m $14.1m $75.0m $60.0m $25.1m
Net Cash Provided by (Used in) Financing Activities $135.6m $33.5m ($117.2m) $2.0m $286.5m ($89.3m) $436.7m ($140.2m) ($60.6m) ($110.2m)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $57.5m ($34.5m) $146.6m $170.0m $176.7m $189.0m $176.2m $240.0m $96.6m $252.2m
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities $284k $139k $582k $709k $19.0m $17.6m $52.5m $73.3m $62.4m $68.8m
Income Taxes Paid, Net — — — — $483k $3.0m $10.4m $24.2m $52.1m $60.0m

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.